Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Megan Othus

Showing results (131-140 of 232) with videos related to

Pageof 24
Sort By:
Leukemia & Lymphoma|March 23, 2021
Effect of post-treatment MRD status on subsequent outcomes according to chemotherapy intensity in acute myeloid leukemia (AML)Michael J Hochman, Megan Othus, Roland B Walter, et al.
Leukemia & Lymphoma|March 9, 2023
Poor post-induction outcomes in patients with acute myeloid leukemia previously treated with hypomethylating agentsMichelle Y Zhang, Megan Othus, Carole Shaw, et al.
Blood Advances|April 25, 2020
A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)Jeffrey E Lancet, Anna B Moseley, Steven E Coutre, et al.
Leukemia Research|January 14, 2014
Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432Harry P Erba, Megan Othus, Roland B Walter, et al.
Leukemia Research|January 29, 2016
Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patientsNicholas J Achille, Megan Othus, Kathleen Phelan, et al.
JAMA Oncology|September 11, 2015
Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative AnalysisJennifer E Vaughn, Megan Othus, Morgan A Powell, et al.
Cancers|May 13, 2023
Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature ReviewIslam Eljilany, Arish Noor, Mahati Paravathaneni, et al.
Haematologica|September 22, 2022
Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantationEduardo Rodríguez-Arbolí, Megan Othus, Corentin Orvain, et al.
Leukemia|July 31, 2023
Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classificationMichael J Hochman, Megan Othus, Robert P Hasserjian, et al.
Leukemia|December 5, 2019
Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual diseaseLinde M Morsink, Evandro D Bezerra, Megan Othus, et al.
Pageof 24

Showing results (131-140 of 232) with videos related to

Sort By:
Pageof 24
Leukemia & Lymphoma|March 23, 2021
Effect of post-treatment MRD status on subsequent outcomes according to chemotherapy intensity in acute myeloid leukemia (AML)Michael J Hochman, Megan Othus, Roland B Walter, et al.
Leukemia & Lymphoma|March 9, 2023
Poor post-induction outcomes in patients with acute myeloid leukemia previously treated with hypomethylating agentsMichelle Y Zhang, Megan Othus, Carole Shaw, et al.
Blood Advances|April 25, 2020
A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)Jeffrey E Lancet, Anna B Moseley, Steven E Coutre, et al.
Leukemia Research|January 14, 2014
Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432Harry P Erba, Megan Othus, Roland B Walter, et al.
Leukemia Research|January 29, 2016
Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patientsNicholas J Achille, Megan Othus, Kathleen Phelan, et al.
JAMA Oncology|September 11, 2015
Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative AnalysisJennifer E Vaughn, Megan Othus, Morgan A Powell, et al.
Cancers|May 13, 2023
Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature ReviewIslam Eljilany, Arish Noor, Mahati Paravathaneni, et al.
Haematologica|September 22, 2022
Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantationEduardo Rodríguez-Arbolí, Megan Othus, Corentin Orvain, et al.
Leukemia|July 31, 2023
Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classificationMichael J Hochman, Megan Othus, Robert P Hasserjian, et al.
Leukemia|December 5, 2019
Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual diseaseLinde M Morsink, Evandro D Bezerra, Megan Othus, et al.
Pageof 24